ZNF217
Zinc finger protein 217, also known as ZNF217, is a protein which in humans is encoded by the ZNF217 gene.[1][2]
Function
ZNF217 can attenuate apoptotic signals resulting from telomere dysfunction and may promote neoplastic transformation and later stages of malignancy.[3] Znf217 was shown to be a prognostic biomarker and therapeutic target during breast cancer progression.[4]
See also
References
- ↑ Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, Cloutier T, Kuo WL, Yaswen P, Dairkee S, Giovanola J, Hutchinson GB, Isola J, Kallioniemi OP, Palazzolo M, Martin C, Ericsson C, Pinkel D, Albertson D, Li WB, Gray JW (Jul 1998). "Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma". Proceedings of the National Academy of Sciences of the United States of America 95 (15): 8703–8. doi:10.1073/pnas.95.15.8703. PMC 21140. PMID 9671742.
- ↑ "Entrez Gene: ZNF217 zinc finger protein 217".
- ↑ Huang G, Krig S, Kowbel D, Xu H, Hyun B, Volik S, Feuerstein B, Mills GB, Stokoe D, Yaswen P, Collins C (Nov 2005). "ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction". Human Molecular Genetics 14 (21): 3219–25. doi:10.1093/hmg/ddi352. PMID 16203743.
- ↑ Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z (Jul 2012). "The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression". Cancer Discovery 2 (7): 638–51. doi:10.1158/2159-8290.CD-12-0093. PMC 3546490. PMID 22728437.
Further reading
- Quinlan KG, Verger A, Yaswen P, Crossley M (Jun 2007). "Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad". Biochimica et Biophysica Acta 1775 (2): 333–40. doi:10.1016/j.bbcan.2007.05.001. PMID 17572303.
- Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM (Mar 1994). "Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization". Proceedings of the National Academy of Sciences of the United States of America 91 (6): 2156–60. doi:10.1073/pnas.91.6.2156. PMC 43329. PMID 8134364.
- Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, Cloutier T, Kuo WL, Yaswen P, Dairkee S, Giovanola J, Hutchinson GB, Isola J, Kallioniemi OP, Palazzolo M, Martin C, Ericsson C, Pinkel D, Albertson D, Li WB, Gray JW (Jul 1998). "Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma". Proceedings of the National Academy of Sciences of the United States of America 95 (15): 8703–8. doi:10.1073/pnas.95.15.8703. PMC 21140. PMID 9671742.
- Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P (Feb 2001). "The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells". Cancer Research 61 (4): 1250–4. PMID 11245413.
- Hakimi MA, Dong Y, Lane WS, Speicher DW, Shiekhattar R (Feb 2003). "A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes". The Journal of Biological Chemistry 278 (9): 7234–9. doi:10.1074/jbc.M208992200. PMID 12493763.
- Weiss MM, Snijders AM, Kuipers EJ, Ylstra B, Pinkel D, Meuwissen SG, van Diest PJ, Albertson DG, Meijer GA (Jul 2003). "Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization". The Journal of Pathology 200 (3): 320–6. doi:10.1002/path.1359. PMID 12845628.
- Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villén J, Li J, Cohn MA, Cantley LC, Gygi SP (Aug 2004). "Large-scale characterization of HeLa cell nuclear phosphoproteins". Proceedings of the National Academy of Sciences of the United States of America 101 (33): 12130–5. doi:10.1073/pnas.0404720101. PMC 514446. PMID 15302935.
- Shimada M, Imura J, Kozaki T, Fujimori T, Asakawa S, Shimizu N, Kawaguchi R (Apr 2005). "Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization". Oncology Reports 13 (4): 633–41. doi:10.3892/or.13.4.633. PMID 15756435.
- Huang G, Krig S, Kowbel D, Xu H, Hyun B, Volik S, Feuerstein B, Mills GB, Stokoe D, Yaswen P, Collins C (Nov 2005). "ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction". Human Molecular Genetics 14 (21): 3219–25. doi:10.1093/hmg/ddi352. PMID 16203743.
- Quinlan KG, Nardini M, Verger A, Francescato P, Yaswen P, Corda D, Bolognesi M, Crossley M (Nov 2006). "Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins". Molecular and Cellular Biology 26 (21): 8159–72. doi:10.1128/MCB.00680-06. PMC 1636751. PMID 16940172.
- Cowger JJ, Zhao Q, Isovic M, Torchia J (May 2007). "Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence". Oncogene 26 (23): 3378–86. doi:10.1038/sj.onc.1210126. PMID 17130829.
External links
- ZNF217 protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Wednesday, March 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.